CAPPED BONUS-ZERTIFIKAT - GILEAD SCIENCES | Market Closed - Deutsche Boerse AG 09:44:21 28/05/2024 pm IST | ||
| 66.61 EUR | -10.19% |
|
| Current month | -5.92% | ||
| 1 month | -4.21% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
More news
| Date | Price | Change |
|---|---|---|
| 28/24/28 | 66.61 | -10.19% |
| 27/24/27 | 74.17 | +1.12% |
| 24/24/24 | 73.35 | -4.85% |
| 23/24/23 | 77.09 | -7.86% |
| 22/24/22 | 83.67 | +3.68% |
Delayed Quote Deutsche Boerse AG
Last update May 28, 2024 at 09:44 pm IST
More quotesStatic data
| Product type | Bonus- und Teilschutz-Zertifikate |
|---|---|
| Buy / Sell | CALL |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | 
Citi
|
| WKN | KH5F1G |
| ISIN | DE000KH5F1G3 |
| Date issued | 27/04/2023 |
| Strike | 99 $ |
| Maturity | 20/06/2024 (23 Days) |
| Parity | 1 : 1 |
| Emission price | 76.37 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 86.86 € |
|---|---|
| Lowest since issue | 64.73 € |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
63.94
USD
Average target price
82.77
USD
Spread / Average Target
+29.46%
- Stock Market
- Certificates
- Certificat
